# A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06305247/  
OnCo record `nct06305247` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IPN01194 in melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and colorectal cancer, run by Ipsen, active and no longer recruiting.

## Summary

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06305247 by Ipsen, with 36 participants enrolled, started 2024-04-03 and due to reach its primary completion in 2028-03-20. Interventions recorded: IPN01194.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06305247
- Phase: 1/2
- Setting: An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours
- Sponsor: Ipsen
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06305247: https://clinicaltrials.gov/study/NCT06305247

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct06305247.json